Showing results (101-110 of 133) with videos related to
Sort By:
Pageof 14
Brain : a Journal of Neurology|June 1, 1993
Congenital endplate acetylcholinesterase deficiencyD O Hutchinson, T J Walls, S Nakano, et al.Journal of Student-Run Clinics|January 30, 2024
Evaluation and Optimization of Diabetic Retinopathy Screenings for Uninsured Latinx Patients in a Resource-Limited Student-Run Free ClinicJennifer J Bu, Arash Delavar, John Kevin Dayao, et al.The Journal of Investigative Dermatology|January 30, 2026
3D Imaging for Facial Vitiligo: Results From a Phase 2 Randomized Controlled Trial Investigating Upadacitinib in Patients With VitiligoAnand K Ganesan, Khaled Ezzedine, Sameh Hanna, et al.Lancet (London, England)|May 28, 2019
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 studyJosef S Smolen, Aileen L Pangan, Paul Emery, et al.Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateMark C Genovese, Josef S Smolen, Michael E Weinblatt, et al.Bioorganic & Medicinal Chemistry Letters|January 20, 2007
The synthesis and structure-activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: polar region modificationsXiangdong Xu, Moshe Weitzberg, Robert F Keyes, et al.Eclinicalmedicine|April 7, 2025
Corrigendum to "Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study" [eClinicalMedicine 73(2024) 102655]Thierry Passeron, Khaled Ezzedine, Lltefat Hamzavi, et al.Arthritis Research & Therapy|July 29, 2024
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trialRonald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, et al.Eclinicalmedicine|June 14, 2024
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging studyThierry Passeron, Khaled Ezzedine, Iltefat Hamzavi, et al.Journal of Glaucoma|March 6, 2023
Usability and Clinician Acceptance of a Deep Learning-Based Clinical Decision Support Tool for Predicting Glaucomatous Visual Field ProgressionJimmy S Chen, Sally L Baxter, Astrid van den Brandt, et al.Pageof 14